PRISYS Translational Research Center for NHP preclinical research
The PRISYS Translational Research Center (PTRC) is Prisys Biotech's non-human primate (NHP) research facility in Fengxian, Shanghai. It brings together NHP disease models, clinical imaging, surgical and post-surgical capabilities, laboratory services, and study teams to support preclinical drug research and translational development.
PTRC supports studies that assess disease biology, pharmacology, efficacy, safety, biomarkers, and imaging endpoints. Depending on the study question, services can include protocol design, model selection, in vivo procedures, longitudinal monitoring, sample analysis, data interpretation, and reporting.
Research capabilities at PTRC
NHP disease models and pharmacology
Prisys Biotech develops and conducts NHP studies across multiple therapeutic areas. Current research areas include:
- CNS and neurology;
- immunology and inflammation;
- metabolic disease and metabolic disease;
- nephrology and cardiorenal research;
- respiratory disease;
- bleeding and clotting;
- fibrosis; and
- ophthalmology.
The model, study design, and endpoint package are selected according to the therapeutic target, mechanism of action, modality, and development question. Model availability and development status are confirmed during protocol planning.
Clinical imaging platform
PTRC's clinical imaging platform supports anatomical assessment, disease characterization, procedure guidance, and longitudinal monitoring. Available modalities include:
- MRI;
- CT;
- digital subtraction angiography (DSA);
- PET-CT;
- DEXA; and
- ultrasound.
Imaging protocols can be adapted to the model and target organ. Depending on the study, imaging may be combined with clinical observations, biosampling, histopathology, pharmacology, or other functional measurements.
Surgical and post-surgical capabilities
PTRC includes clinical sterile operating rooms and post-surgical intensive care capabilities for studies that require surgical procedures, device placement, vascular access, or recovery monitoring. Surgical planning, peri-operative monitoring, post-operative care, and follow-up are defined by the approved study protocol and animal-welfare review.
BSL-2 and ABSL-2 laboratory capabilities
PTRC includes BSL-2 laboratory space for work such as microbial, cellular, molecular, and transgenic research. The associated ABSL-2 in vivo laboratories use negative-pressure filtration for studies that require animal biosafety containment.
Depending on the approved project, laboratory activities may include tissue culture, sample processing and analysis, dissection, aerobiology, vaccine immunology, and other protocol-defined procedures. Facility use is subject to the applicable biosafety review, containment requirements, and institutional approvals.
NHP behavior and neurological assessment
For CNS programs, PTRC can combine NHP disease models with clinical assessment, imaging, electrophysiology, and AI-based behavioral analysis. Prisys uses synchronized multi-view video and deep-learning methods for markerless 3D behavior analysis. It can reconstruct a skeletal representation and estimate predefined behavior states on a seconds scale.
Behavior endpoints are selected for the study question and may be combined with MRI, PET-CT, electrophysiology, PK/PD, CSF sampling, or other protocol-defined readouts.
MRI-guided intracranial delivery
For selected CNS programs, PTRC supports MRI-guided intracranial procedures and convection-enhanced delivery (CED). ClearPoint® navigation, an MRI-compatible microcatheter, and real-time imaging can be used to plan and monitor delivery to deep-brain targets.
The suitability of this workflow depends on the therapeutic modality, target, procedure, and study protocol. Detailed platform information and reported performance data should be presented on the relevant CNS delivery page and used only after scientific and commercial review.
From study question to report
PTRC can support a preclinical NHP project through a coordinated workflow:
- Study discussion and design: define the target, mechanism, therapeutic modality, and development decision the study must inform.
- Model and endpoint selection: identify a suitable NHP model and agree on clinical, imaging, laboratory, and functional readouts.
- Protocol and review: finalize procedures, sampling, monitoring, analysis, and applicable ethical and biosafety reviews.
- Study execution: conduct approved procedures, dosing, monitoring, imaging, and sample collection.
- Analysis and reporting: interpret the findings against the protocol objectives and provide study data and a report for the sponsor's development decisions.
The scope, timelines, deliverables, and compliance requirements are defined for each project. PTRC supports preclinical research; it does not replace sponsor responsibilities for clinical development or regulatory submissions.
Quality, animal welfare, and oversight
PTRC is an AAALAC-accredited NHP facility with IACUC oversight, biosafety controls, and animal-welfare enrichment programs. Study procedures, housing, veterinary care, and monitoring follow applicable facility policies, approved protocols, and regulatory requirements.
The accreditation and quality-system statements on the live page should match current certificates and corporate-approved wording. Do not imply that every study or service is certified to a particular regulatory standard unless that scope is documented.
Frequently asked questions
Q: What is the PRISYS Translational Research Center?
A: PTRC is Prisys Biotech's NHP research facility in Shanghai. It brings together disease models, clinical imaging, surgical and post-surgical capabilities, laboratory services, and study teams for preclinical research.
Q: Where is PTRC located?
A: PTRC is located in Fengxian, Shanghai, China. Contact Prisys Biotech for facility access and project discussions.
Q: What types of studies can PTRC support?
A: PTRC supports NHP preclinical studies that may include pharmacology, efficacy, safety-related assessments, disease-model research, imaging, biomarker analysis, and therapeutic target or mechanism studies. The services used in a project depend on the protocol and scientific objective.
Q: What imaging modalities are available at PTRC?
A: PTRC's imaging modalities include MRI, CT, DSA, PET-CT, DEXA, and ultrasound. The imaging method and protocol are selected according to the target organ, study design, and required endpoints.
Q: Does PTRC include operating rooms and post-surgical care?
A: Yes. The center includes clinical sterile operating rooms and post-surgical intensive care capabilities for approved studies that require surgery or recovery monitoring. Procedures and care plans are defined in the study protocol.
Q: What do the BSL-2 and ABSL-2 facilities support?
A: BSL-2 laboratory capabilities support approved microbial, cellular, molecular, and related research. ABSL-2 in vivo facilities provide animal containment for studies that require the applicable biosafety controls. All activities are subject to project-specific biosafety review and approval.
Q: Can imaging, behavior, and laboratory endpoints be combined in one study?
A: Yes. When scientifically appropriate, a protocol can combine imaging with behavioral or clinical assessments, biosampling, laboratory assays, electrophysiology, PK/PD, and histopathology. The combination is determined by the study question and approved protocol.
Q: What disease areas are represented at PTRC?
A: Prisys NHP research areas include CNS and neurology, immunology and inflammation, metabolic disease, nephrology, respiratory disease, bleeding and clotting, fibrosis, and ophthalmology. Model availability and development status vary by indication and should be confirmed during project planning.
Discuss a study at PTRC
To discuss an NHP preclinical program, contact Prisys Biotech withthe therapeutic area, target or mechanism, modality, and the decision your study needs to support. The study team can then discuss model fit, required endpoints, facility capabilities, and a project-specific protocol.
